Hairy Cell Leukemia Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Hairy cell leukemia is a rare, slow-growing cancer of the blood in which bone marrow makes too many B cells (lymphocytes), a type of white blood cell that fights infection. Symptoms include fatigue, easy bruising, recurring infections, weakness and weight loss. Risk factors include exposure to radiation, chemicals and saw dust. Treatment includes surgery, chemotherapy and radiation therapy.
The Hairy Cell Leukemia pipeline drugs market research report outlays comprehensive information on the Hairy Cell Leukemia targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type, that are being developed by companies/universities. It also reviews key players involved in Hairy Cell Leukemia targeted therapeutics development with respective active and dormant or discontinued projects.
Hairy Cell Leukemia Pipeline Drugs Market Segmentation by Targets
Some of the primary targets in the Hairy Cell Leukemia pipeline drugs market are Cells Expressing B Lymphocyte Antigen CD19, Cells Expressing B Cell Receptor CD22, Cells Expressing B Lymphocyte Antigen CD20, Serine/Threonine Protein Kinase B Raf, Tyrosine Protein Kinase BTK, Dual Specificity Mitogen Activated Protein Kinase Kinase 1, Dual Specificity Mitogen Activated Protein Kinase Kinase 2, Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Delta Isoform, B Cell Lymphoma 2, and CD3.
Hairy Cell Leukemia Pipeline Drugs Market Analysis, by Targets
To know more about the targets in the Hairy Cell Leukemia pipeline drugs market, download a free report sample
Hairy Cell Leukemia Pipeline Drugs Market Segmentation by Mechanisms of Action
The primary mechanisms of action in the Hairy Cell Leukemia pipeline drugs market are Cytotoxic To Cells Expressing B Lymphocyte Antigen CD19, Cytotoxic To Cells Expressing B Cell Receptor CD22, Cytotoxic To Cells Expressing B Lymphocyte Antigen CD20, Serine/Threonine Protein Kinase B Raf Inhibitor, Tyrosine Protein Kinase BTK Inhibitor, Dual Specificity Mitogen Activated Protein Kinase Kinase 1 Inhibitor, Dual Specificity Mitogen Activated Protein Kinase Kinase 2 Inhibitor, Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Delta Isoform Inhibitor, B Cell Lymphoma 2 Inhibitor, and CD3 Agonist.
Hairy Cell Leukemia Pipeline Drugs Market Analysis, by Mechanisms of Action
To know more about the MoA in the Hairy Cell Leukemia pipeline drugs market, download a free report sample
Hairy Cell Leukemia Pipeline Drugs Market Segmentation by Routes of Administration
The key routes of administration in the Hairy Cell Leukemia pipeline drugs market are Oral, Intravenous, Parenteral, Intralesional, and Subcutaneous.
Hairy Cell Leukemia Pipeline Drugs Market Analysis, by Routes of Administration
To know more about the RoA in the Hairy Cell Leukemia pipeline drugs market, download a free report sample
Hairy Cell Leukemia Pipeline Drugs Market Segmentation by Molecule Type
The key molecule types in the Hairy Cell Leukemia pipeline drugs market are Gene-Modified Cell Therapy, Small Molecule, Monoclonal Antibody, Biologic, Monoclonal Antibody Conjugated, and Recombinant Protein.
Hairy Cell Leukemia Pipeline Drugs Market Analysis, by Molecule Type
To know more about the molecule type in the Hairy Cell Leukemia pipeline drugs market, download a free report sample
Competitive Landscape
Some of the leading companies in the Hairy Cell Leukemia pipeline drugs market are F. Hoffmann-La Roche Ltd, Incyte Corp, Wuhan Bio-Raid Biotechnology Co Ltd, AstraZeneca Plc, AbbVie Inc, Ascentage Pharma Group International, Autolus Therapeutics Plc, Bristol-Myers Squibb Co, Eureka Therapeutics Inc, and Jecho Biopharmaceuticals Co Ltd.
Hairy Cell Leukemia Pipeline Drugs Market Analysis, by Leading Companies
To know more about the leading companies in the Hairy Cell Leukemia pipeline drugs market, download a free report sample
Hairy Cell Leukemia Pipeline Drugs Market Report Overview
Key Targets | Cells Expressing B Lymphocyte Antigen CD19, Cells Expressing B Cell Receptor CD22, Cells Expressing B Lymphocyte Antigen CD20, Serine/Threonine Protein Kinase B Raf, Tyrosine Protein Kinase BTK, Dual Specificity Mitogen Activated Protein Kinase Kinase 1, Dual Specificity Mitogen Activated Protein Kinase Kinase 2, Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Delta Isoform, B Cell Lymphoma 2, and CD3 |
Key Mechanisms of Action | Cytotoxic To Cells Expressing B Lymphocyte Antigen CD19, Cytotoxic To Cells Expressing B Cell Receptor CD22, Cytotoxic To Cells Expressing B Lymphocyte Antigen CD20, Serine/Threonine Protein Kinase B Raf Inhibitor, Tyrosine Protein Kinase BTK Inhibitor, Dual Specificity Mitogen Activated Protein Kinase Kinase 1 Inhibitor, Dual Specificity Mitogen Activated Protein Kinase Kinase 2 Inhibitor, Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Delta Isoform Inhibitor, B Cell Lymphoma 2 Inhibitor, and CD3 Agonist |
Key Routes of Administration | Oral, Intravenous, Parenteral, Intralesional, and Subcutaneous |
Key Molecule Types | Gene-Modified Cell Therapy, Small Molecule, Monoclonal Antibody, Biologic, Monoclonal Antibody Conjugated, and Recombinant Protein |
Key Companies | F. Hoffmann-La Roche Ltd, Incyte Corp, Wuhan Bio-Raid Biotechnology Co Ltd, AstraZeneca Plc, AbbVie Inc, Ascentage Pharma Group International, Autolus Therapeutics Plc, Bristol-Myers Squibb Co, Eureka Therapeutics Inc, and Jecho Biopharmaceuticals Co Ltd |
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Hairy Cell Leukemia (Oncology).
- The pipeline guide reviews pipeline therapeutics for Hairy Cell Leukemia (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Hairy Cell Leukemia (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Hairy Cell Leukemia (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Hairy Cell Leukemia (Oncology)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Hairy Cell Leukemia (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Hairy Cell Leukemia (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Key Players
Table of Contents
List of Tables
List of Figures
Frequently Asked Questions
Some of the targets in the Hairy Cell Leukemia pipeline drugs market are Cells Expressing B Lymphocyte Antigen CD19, Cells Expressing B Cell Receptor CD22, Cells Expressing B Lymphocyte Antigen CD20, Serine/Threonine Protein Kinase B Raf, Tyrosine Protein Kinase BTK, Dual Specificity Mitogen Activated Protein Kinase Kinase 1, Dual Specificity Mitogen Activated Protein Kinase Kinase 2, Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Delta Isoform, B Cell Lymphoma 2, and CD3.
The primary mechanism of action in the Hairy Cell Leukemia pipeline drugs market are Cytotoxic To Cells Expressing B Lymphocyte Antigen CD19, Cytotoxic To Cells Expressing B Cell Receptor CD22, Cytotoxic To Cells Expressing B Lymphocyte Antigen CD20, Serine/Threonine Protein Kinase B Raf Inhibitor, Tyrosine Protein Kinase BTK Inhibitor, Dual Specificity Mitogen Activated Protein Kinase Kinase 1 Inhibitor, Dual Specificity Mitogen Activated Protein Kinase Kinase 2 Inhibitor, Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Delta Isoform Inhibitor, B Cell Lymphoma 2 Inhibitor, and CD3 Agonist.
The routes of administration in the Hairy Cell Leukemia pipeline drugs market are Oral, Intravenous, Parenteral, Intralesional, and Subcutaneous.
The molecule types in the Hairy Cell Leukemia pipeline drugs market are Gene-Modified Cell Therapy, Small Molecule, Monoclonal Antibody, Biologic, Monoclonal Antibody Conjugated, and Recombinant Protein.
Some of the leading companies in the Hairy Cell Leukemia pipeline drugs market are F. Hoffmann-La Roche Ltd, Incyte Corp, Wuhan Bio-Raid Biotechnology Co Ltd, AstraZeneca Plc, AbbVie Inc, Ascentage Pharma Group International, Autolus Therapeutics Plc, Bristol-Myers Squibb Co, Eureka Therapeutics Inc, and Jecho Biopharmaceuticals Co Ltd.
Get in touch to find out about our multi-purchase discounts
reportstore@globaldata.com
Tel +44 (0) 20 7947 2960
Every customer’s requirement is unique. We understand that and can customize the report basis your exact research requirements pertaining to market insights, innovation insights, strategy and planning, and competitive intelligence. You can also avail the option of purchasing stand-alone sections of the report or request for a country specific report.
Still undecided about purchasing this report?
Testimonial
“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.
GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”
“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”
Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.
Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.